BlackRock’s Achieve Life Sciences ACHV Stock Holding History

BlackRock’s Portfolio ACHV Stock Details ACHV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.29M	Buy	439,360 +20,227	+5%	+$89.8K	﹤0.01%	4248
2025 Q4	$2.08M	Buy	419,133 +27,893	+7%	+$122K	﹤0.01%	4107
2025 Q3	$1.23M	Buy	391,240 +76,541	+24%	+$210K	﹤0.01%	4230
2025 Q2	$711K	Sell	314,699 -1,739,315	-85%	-$4.95M	﹤0.01%	4362
2025 Q1	$5.48M	Sell	2,054,014 -32,486	-2%	-$101K	﹤0.01%	3615
2024 Q4	$7.34M	Buy	2,086,500 +15,368	+0.7%	+$69.6K	﹤0.01%	3574
2024 Q3	$9.82M	Buy	2,071,132 +114,622	+6%	+$524K	﹤0.01%	3419
2024 Q2	$9.2M	Buy	1,956,510 +1,904,079	+3,632%	+$9.17M	﹤0.01%	3430
2024 Q1	$238K	Hold	52,431	–	–	﹤0.01%	4547
2023 Q4	$216K	Sell	52,431 -154	-0.3%	-$671	﹤0.01%	4620
2023 Q3	$226K	Hold	52,585	–	–	﹤0.01%	4644
2023 Q2	$273K	Buy	52,585 +39,731	+309%	+$279K	﹤0.01%	4656
2023 Q1	$87.4K	Sell	12,854 -1,227	-9%	-$5.83K	﹤0.01%	4986
2022 Q4	$34.5K	Hold	14,081	–	–	﹤0.01%	5298
2022 Q3	$47K	Hold	14,081	–	–	﹤0.01%	5372
2022 Q2	$69K	Sell	14,081 -1,126	-7%	-$7.64K	﹤0.01%	5345
2022 Q1	$115K	Hold	15,207	–	–	﹤0.01%	5254
2021 Q4	$119K	Buy	15,207 +12,470	+456%	+$98K	﹤0.01%	5218
2021 Q3	$23K	Buy	2,737 +2,410	+737%	+$18.9K	﹤0.01%	5385
2021 Q2	$3K	Sell	327 -58	-15%	-$552	﹤0.01%	5398
2021 Q1	$4K	Sell	385 -37	-9%	-$439	﹤0.01%	5151
2020 Q4	$4K	Hold	422	–	–	﹤0.01%	4918
2020 Q3	$4K	Sell	422 -1	-0.2%	-$9	﹤0.01%	4865
2020 Q2	$4K	Hold	423	–	–	﹤0.01%	4848
2020 Q1	$3K	Hold	423	–	–	﹤0.01%	4804
2019 Q4	$4K	Hold	423	–	–	﹤0.01%	4804
2019 Q3	$14K	Hold	423	–	–	﹤0.01%	4684
2019 Q2	$17K	Hold	423	–	–	﹤0.01%	4706
2019 Q1	$27K	Hold	423	–	–	﹤0.01%	4559
2018 Q4	$10K	Hold	423	–	–	﹤0.01%	4663
2018 Q3	$27K	Hold	423	–	–	﹤0.01%	4618
2018 Q2	$32K	Buy	423 +3	+0.7%	+$611	﹤0.01%	4613
2018 Q1	$106K	Buy	420 +3	+0.7%	+$858	﹤0.01%	4330
2017 Q4	$112K	Buy	417 +5	+1%	+$1.6K	﹤0.01%	4319
2017 Q3	$167K	Sell	412 -10	-2%	-$7.18K	﹤0.01%	4263
2017 Q2	$334K	Sell	422 -13	-3%	-$10.5K	﹤0.01%	4120
2017 Q1	$423K	Buy	+435	New	+$528K	﹤0.01%	4010
2014 Q2	–	Hold	0	–	-$6K	–	3152
2014 Q1	–	Hold	0	–	–	–	2985
2013 Q4	–	Hold	0	–	–	–	3085
2013 Q3	–	Hold	0	–	–	–	2979
2013 Q2	–	Hold	0	–	–	–	3019

Other funds holding ACHV

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock's ACHV Position: Q1 2026 in Review

BlackRock increased its Achieve Life Sciences (ACHV) stake by 4.8% in Q1 2026, buying an estimated $89.8K and bringing the position to 439,360 shares worth $1.29M. The position accounts for ﹤0.01% of the portfolio, ranked #4248.

BlackRock first reported a position in ACHV in Q1 2017 and has held it in 37 quarters since. The position peaked at $9.82M in Q3 2024. 81 funds tracked by Wall St. Rank hold ACHV as of Q1 2026.

BlackRock held 439,360 shares of Achieve Life Sciences worth $1.29M as of Q1 2026.
BlackRock bought 20,227 Achieve Life Sciences shares in Q1 2026, an estimated $89.8K.
Achieve Life Sciences made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4248 holding.
BlackRock first reported a position in Achieve Life Sciences in Q1 2017 and has held it in 37 quarters since.
BlackRock's Achieve Life Sciences position peaked at $9.82M in Q3 2024.
81 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.